Simonetta Federico

Dr. Federico Simonetta

Chef de Clinique Scientifique Oncology, Division of Hematology


I am currently a "chef de clinique scientifique" (50% clinical, 50% research) within the Division of Hematology, Department of Oncology, HUG. After my MD from University of Genoa, Italy, I obtained a MSc in Immunology form Pasteur Institute/University of Paris-VII and a PhD in Immunology form University of Paris-Sud. I then did my postgraduate training in Internal Medicine and Hematology at HUG. In 2016, I joined the lab of Pr. RS Negrin at Stanford University as a postdoctoral fellow. I came back in 2020 hosted for my research activity in the lab of Pr. J. Tamburini at CRTOH. I am member of the Working group for Cellular Therapies of the SAKK and the SBST and of the Swiss Board on Multiple Myeloma CAR T cells. I am co-chair of the Immune monitoring subcommittee of the Cellular Therapy & Immunobiology Working Party(CTIWP) of the European Society for Blood and Marrow Transplantation (EBMT). Within the CRTOH, I have several established collaborations (Pr. Jérôme Tamburini, Pr. Camilla Jandus) around acute myeloid leukemia.

My clinical work is mainly focused on Chimeric Antigen Receptor (CAR) T cells and allogeneic hematopoietic stem cell transplantation (HSCT). I am the medical coordinator of the CAR T cell program that we started at HUG in 2021. My main research interest is the development of immune-effector and immune-regulatory allogeneic cellular therapies for treatment of hematologic malignancies and graft-versus-host-disease (GvHD) respectively. In addition, I study mechanisms of immune-reconstitution after allogeneic HSCT and CAR T cell therapy with a particular focus on the identification of biomarkers for immune-monitoring. We combine in vitro studies with ex vivo analysis on clinical samples obtained from patients from the allogeneic HSCT program led by Pr. Yves Chalandon. In addition, I have several local (Pr. Laurent Kaiser, HUG), national (Pr. Francesco Bertoni, IOR, Bellinzona) and international (Pr. Antonio Pierini, University of Perugia, Italy; Pr. Robert S. Negrin, Stanford University, USA) collaborations around these research topics.


  • Pradier A, Mamez AC, Stephan C, Giannotti F, Masouridi-Levrat S, Wang S, Morin S, Neofytos D, Vu DL, Melotti A, Arm I, Eberhardt CS, Tamburini J, Kaiser L, Chalandon Y, Simonetta F. T Cell Receptor Sequencing Reveals Reduced Clonal Breadth of T Cell Responses against SARS-CoV-2 after Natural Infection and Vaccination in Allogeneic Hematopoietic Stem Cell Transplant Recipients. Ann Oncol. 2022 Sep 15:S0923-7534(22)04144-8.
  • Simonetta F, Lohmeyer JK, Hirai T, Maas-Bauer K, Alvarez M, Wenokur AS, Baker J, Aalipour A, Ji X, Haile S, Mackall CL, Negrin RS. Allogeneic CAR Invariant Natural Killer T Cells Exert Potent Antitumor Effects through Host CD8 T-Cell Cross-Priming. Clin Cancer Res. 2021 Nov 1;27(21):6054-6064.
  • Maas-Bauer K, Lohmeyer JK, Hirai T, Ramos TL, Fazal FM, Litzenburger UM, Yost KE, Ribado JV, Kambham N, Wenokur AS, Lin PY, Alvarez M, Mavers M, Baker J, Bhatt AS, Chang HY, Simonetta F*, Negrin RS*. Invariant natural killer T-cell subsets have diverse graft-versus-host-disease-preventing and antitumor effects. Blood. 2021 Sep 9;138(10):858-870. (*co-senior author).
  • Simonetta F, Alam IS, Lohmeyer JK, Sahaf B, Good Z, Chen W, Xiao Z, Hirai T, Scheller L, Engels P, Vermesh O, Robinson E, Haywood T, Sathirachinda A, Baker J, Malipatlolla MB, Schultz LM, Spiegel JY, Lee JT, Miklos DB, Mackall CL, Gambhir SS, Negrin RS. Molecular Imaging of Chimeric Antigen Receptor T Cells by ICOS-ImmunoPET. Clin Cancer Res. 2021 Feb 15;27(4):1058-1068.
  • Pradier A, Masouridi-Levrat S, Bosshard C, Dantin C, Vu DL, Zanella MC, Boely E, Tapparel C, Kaiser L, Chalandon Y, Simonetta F*, Roosnek E*. Torque Teno Virus as a Potential Biomarker for Complications and Survival After Allogeneic Hematopoietic Stem Cell Transplantation. Front Immunol. 2020 May 27;11:998. . (*co-senior author)


Link to full publication list here